Biotech Showcase™ 2013 investor and partnering conference will welcome some of the sector’s most innovative biotech companies to San Francisco on January 7–9. The event will be held at Parc 55 Wyndham San Francisco – Union Square, and is expected to draw over 1,000 executives from the life sciences.
Attending companies include Acorda Therapeutics, Biodesix, Blend Therapeutics, Contrafect Corporation, Cytori Therapeutics , Livtech, Inc., PTC Therapeutics and Sucampo Pharmaceuticals, among many.
“This forum provides one of the best crossroads for companies to meet with a concentration of high caliber private and public investors, the investment banking community and potential business partners,” said Julia P. Gregory, Executive VP and CFO of Contrafect Corporation. “It is our goal to provide visibility to our new approach to anti-infectives using our unique biotherapeutics to fight resistant, life-threatening staph infections. It’s a great way to kick off the new year.”
“Biotech Showcase is a premier opportunity for PTC to interact with biopharmaceutical community and discuss shared interests,” said Cláudia Hirawat, President of PTC Therapeutics. “It is a fantastic venue to start the year and explore new opportunities.”
“For CEOs, this event is about getting exposure, building a profile, having the opportunity to network with investors, and the fact that Biotech Showcase fills a major need for private and small cap companies,” said Sara Jane Demy, President of Demy-Colton Life Science Advisors. “Biotech Showcase is an investor conference, and companies are interested in building their profile and visibility with investors for the future.”
“Attending companies represent state-of-the-art products, services, and research in biotechnology, and this is a real draw for investors who are in the city for the largest annual healthcare investor conference,” said Carola Schropp, President of EBD Group. “Biotech Showcase provides investors firsthand access to innovative ideas in the biopharma sector.”
Participants include private and public equity investors, industry analysts, bankers, pharmaceutical and biotechnology industry executives as well as other industry professionals. The 2013 edition will feature nearly 230+ corporate presentations as well as a robust program that will address the current environment for investment and growth, best practices, important therapeutic areas and business development.
Biotech Showcase is co-produced annually by EBD Group, Inc. and Demy-Colton Life Science Advisors. Both organizations have a long history of providing high quality business support programs and services to the biotechnology industry.
Biotech Showcase is powered by partneringONE®, the industry’s most advanced partnering system, that enables delegates to efficiently identify and arrange meetings with potential investors and partners. Partnering opened December 5. Request meetings by logging onto your account at www.ebdgroup.com/bts/partnering/index.php.
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.
EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:
EBD Group’s sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world, and partnering360® is the open online community of life science dealmakers that enhances partnering experiences throughout the year.
EBD Group is an Informa company. Informa is the largest publicly-owned organizer of exhibitions, conferences and training in the world.
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
Biotech Showcase™ is an investor and partnering conference devoted to providing private and small- and mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives during the course of one of the largest annual healthcare conferences that attracts investors and biopharmaceutical executives from around the world.
The 2013 edition showed a substantial increase in the number of presenting companies, as well as significant growth in the number of attendees and one-to-one meetings. The 2013 event featured corporate presentations by 236 public and private biotechnology and life science companies, and drew 1,600 delegates who engaged in 2,500 one-to-one meetings.
Follow Biotech Showcase 2014 on Twitter: twitter.com/ebdgroup (hashtag: #BTS14)